267651-83-2

Upstream product

• 36288-37-6 (Z)-N-hydroxy-4-methylbenzene-1-carbonimidoyl chloride 
• 1104461-74-6 methyl 3-(p-nitrobenzoyloxy)acrylate 
• 36288-37-6 N-hydroxy-4-methylbenzenecarboximidoyl chloride 
• 922-67-8 propynoic acid methyl ester 
• 3235-02-7 p-methylbenzaldehyde oxime 
• 267651-82-1 2-methoxycarbonylvinyl 4-nitrobenzoate 

Downstream Products

• 839717-99-6 3-(4-methylphenyl)isoxazole-4-carboxylic acid 

Relevant academic research and scientific papers

1,3-Dipolar cycloaddition of nitrile oxides to methyl 3-(p- nitrobenzoyloxy)acrylate: Methyl 3-(p-nitrobenzoyloxy)acrylate as a methyl propiolate equivalent with reverse regioselectivity

3-Aryl-4-methoxycarbonylisoxazoles were prepared from the reaction of a variety of substituted benzonitrile oxides with methyl 3-(p- nitrobenzoyloxy)acrylate in moderate to good yields.

DFT-HSAB prediction of regioselectivity in 1,3-dipolar cycloadditions: Behavior of (4-substituted)benzonitrile oxides towards methyl propiolate

The regioselectivity of 1.3-di-polar cycloadditions between (4-substituted)benzonitrile oxides and methyl propiolate cannot be rationalized on the basis of the electron demand of the reactants or frontier molecular-orbital theory. To this problem, we have

Novel azole compound

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.